Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups – Novartis

by

  1. Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups Novartis
  2. Drug cuts risk of breast cancer recurrence for some early-stage patients, trial shows CNN
  3. Novartis drug cuts recurrence risk by 25% in early-stage breast cancer Reuters
  4. ASCO: Novartis details Kisqali’s adjuvant breast cancer win FiercePharma
  5. Breast cancer drug cuts risk of most common form returning by 25% The Guardian
  6. View Full Coverage on Google News

Read original article here

Leave a Comment